Biohaven has started a randomised Phase II/III trial of the TYK2 / JAK1 inhibitor, BHV-8000, aimed at treating early ...

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

Intellia's news comes at a challenging time for gene therapies, as multiple serious adverse events and fatalities have been ...

Entrada has secured the authorisation within the EU Clinical Trial Regulation to begin the Phase I/II trial of ENTR-601-45.

After Lykos' rejection from the FDA last year, companies trying to navigate the psychedelic drug trial sector face various ...

Pfizer’s and Arvinas’ vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) ER degrader which slows tumour growth.

Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

WCG has launched the WCG Study Accelerator, an integrated solution designed to optimise the clinical trial process.

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.

Scynexis has resumed dosing of its vaginal yeast infection drug Brexafemme (ibrexafungerp) in a Phase III trial after a ...

The US-based START Center for Cancer Research (START) and OneOncology have collaborated to introduce three early-phase trial ...